Company profile
Versanis Bio company profile
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults. Versanis Bio is advancing Bimagrumab, a human monoclonal antibody to the activin type II receptors that block the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies, Bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.
Business identity
- Website
- https://www.versanisbio.com
- Contact email
- [email protected]
- Phone number
- (617) 315-4410
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0-$1M
- Founded
- 2021-01-01, Year
Headquarters
- Headquarters
- Rib Lake, Wisconsin, United States
- Postal code
- 94607
- Country code
- US
- Continent
- North America